Characteristics of patients with worsening of steatosis according to the presence or absense of steatosis at diagnosis*
| Patients without steatosis (n=45) | Patients with steatosis (n=42) | |||||
|---|---|---|---|---|---|---|
| Steatosis worsening (n=24) | No steatosis worsening (n=21) | p Value | Steatosis worsening (n=10) | No steatosis worsening (n=32) | p Value | |
| *To study the effect of worsening of steatosis, nine patients with severe steatosis at diagnosis were excluded. | ||||||
| HCV, hepatitis C virus; ALT, alanine aminotransferase; IVDU, intravenous drug use. | ||||||
| Age (y) | 39 (10) | 39 (10) | NS | 41 (140) | 44 (12) | NS |
| Sex (M/F) | 16/8 | 9/12 | NS | 8/2 | 21/11 | NS |
| Source of infection (%) | ||||||
| Transfusion | 38 | 38 | 40 | 53 | ||
| IVDU | 20 | 29 | NS | 40 | 19 | NS |
| Other | 25 | 29 | 20 | 9 | ||
| Unknown | 17 | 4 | 0 | 19 | ||
| Alcohol intake (%) | ||||||
| ≤40 g/day | 83 | 100 | NS | 100 | 87 | NS |
| >40 g/day | 17 | 0 | 0 | 13 | ||
| Body mass index (kg/m2) | 24.6 (2.4) | 23.1 (2.5) | NS | 25.3 (3.0) | 25.7 (3.2) | NS |
| Age at exposure (y) | 25 (14) | 23 (9) | NS | 29 (13) | 31 (11) | NS |
| Interval between biopsies (months) | 56 (39) | 51 (33) | NS | 52 (30) | 41 (27) | NS |
| HCV genotype (%) | ||||||
| 1 | 75 | 57 | 40 | 83 | ||
| 3 | 8 | 14 | NS | 40 | 10 | 0.068 |
| Other | 17 | 29 | 20 | 7 | ||
| Histological lesions (METAVIR) | ||||||
| Evolution of activity (%) | ||||||
| Worsening | 37 | 33 | NS | 50 | 19 | NS |
| Stability/improvement | 63 | 67 | 50 | 71 | ||
| Evolution of fibrosis (%) | ||||||
| Worsening | 50 | 14 | <0.03 | 60 | 19 | 0.03 |
| Stability/improvement | 50 | 86 | 40 | 81 | ||